Innovative Endpoints in Alzheimer’s Disease Clinical Trials
Together with our partner Brain Research Center, we presented the webinar:
Innovative Endpoints in Alzheimer’s Disease Clinical trials.
During this webinar, two experts in the field, Dr. Niels Prins and Dr. Jort Vijverberg discussed the latest clinical and biomarker endpoints.
During this webinar our experts expanded on how we advance clinical drug development for Alzheimer’s disease by touching upon:
> Biomarker-based participant selection;
> inclusion criteria for upcoming AD trials
> Fluid biomarkers as endpoints in your AD trial;
> EEG; a ‘novel’ AD biomarker.
Related webinars
Webinar: Real-World Data in ALS
On 30 May, we hosted the webinar "Real-World Data in ALS", in which we explored the innovative integration of Real World Data (RWD) in clinical trials for Amyotrophic Lateral Sclerosis (ALS). As a critical step forward in the pursuit of effective ...
Webinar: Selecting and successfully integrating cognitive testing into clinical trials
On May 9, we presented the webinar: Selecting and successfully integrating cognitive testing into clinical trialsDuring this webinar, hosted by Dr. Lieza Exalto, speaker Dr. John Harrison discussed:Cognitive domains – which ones sho...
Measuring and tracking everyday functioning in AD clinical trials with the Amsterdam IADL Questionnaire
In collaboration with our partner Brain Research Center, we presented the webinar: Measuring and tracking everyday functioning in AD clinical trials with the Amsterdam IADL QuestionnaireSpeakers:Dr. Sietske Sikkes | Associate Professor a...